Close Menu
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    TopBuzzMagazine.com
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    • Home
    • Movies
    • Television
    • Music
    • Fashion
    • Books
    • Science
    • Technology
    • Cover Story
    • Contact
      • About
      • Amazon Disclaimer
      • Terms and Conditions
      • Privacy Policy
      • DMCA / Copyrights Disclaimer
    TopBuzzMagazine.com
    Home»Science»Vaccine Makers Are Preparing for Bird Flu
    Science

    Vaccine Makers Are Preparing for Bird Flu

    By AdminMarch 5, 2023
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Vaccine Makers Are Preparing for Bird Flu

    Minks in Spain, seals in Scotland, sea lions and dolphins in South America: a number of mammal species have recently been found to be infected with H5N1, a highly pathogenic strain of avian influenza. Avian flu is not new; epidemiologists have been studying it for decades. But the detection of the virus in mammals has many concerned about the potential that it could spill over to humans and cause a larger outbreak.

    As the world enters the fourth year of a global pandemic caused by a virus that likely came from an animal, concern over another virus potentially uprooting our lives is valid. H5N1 has infected humans before, although human-to-human transmission has rarely been observed. And while the World Health Organization (WHO) reports that the mortality rate of avian flu in humans is around 56 percent, many experts believe it’s likely to be much lower if the virus becomes more transmissible. One reason avian flu is so lethal is that it infects the lower respiratory tract, which can lead to respiratory failure. If it were to mutate to infect the upper respiratory tract and spread more easily, it would probably cause milder illness. Yet even a virus that causes mild or moderate illness in many people can have a serious toll, as we’ve seen with the COVID pandemic. So efforts are underway to develop vaccines to protect against such a form of bird flu.

    Bird flu has spilled over to humans before—in fact, just last week a girl in Cambodia died from H5N1 (although not the same strain as the one that is sickening birds worldwide).

    “Each time we see this happen, we get these spurts of cases, [and] people say, ‘Here it comes; it’s going to happen,’” says Michael Osterholm, director of the University of Minnesota’s Center for Infectious Disease Research and Policy. But he stressed that H5N1 is likely not an imminent threat to humans.

    Others agree. “I’m keeping a close eye on it as an expert, but as a member of the community, as a parent and someone who [has been] recently experiencing the COVID-19 pandemic, I’m not worried about this right now,” says Caitlin Rivers, an epidemiologist at the Johns Hopkins Center for Health Security. “This is an animal health issue right now that has a theoretical risk to become a human health issue.”

    Avian influenza viruses infect birds by attaching to a receptor in their respiratory tract. In order for the virus to become a human virus and start circulating from person to person in the population, it would have to be able to attach itself to the human version of this receptor—something it hasn’t yet evolved to do.

    “It’s a really dangerous time to be a bird,” Andrew Pavia, chief of the division of pediatric infectious diseases at the University of Utah, adds. “But as of today, the risk to humans remains very low. Our concern is what’s going to happen as it circulates more and more.”

    It’s unfortunately nearly impossible to predict when this jump could happen. “None of us know when the next influenza pandemic will emerge. It could be tomorrow [or] it could be years from now, and we don’t know which of the viruses will become the next pandemic virus,” Osterholm says. “At the outset, you have to say there is uncertainty, with one exception: there will be a pandemic.”

    The U.S. is somewhat equipped to handle avian flu: there is a stockpile of egg-based flu vaccines for the H5N1 strain. Eggs are one of the most common ways to make a flu vaccine. To create it, manufacturers inject an inactivated or weakened virus into a fertilized chicken egg, incubate the egg for a few days while the virus multiplies and then harvest the virus to use for the vaccine. The country has a secret chicken stockpile in undisclosed locations across the U.S. just in case we need to make egg-based vaccines quickly—such as during a flu pandemic. It may be concerning that this vaccine strategy depends on an animal that is highly susceptible to the flu in question. But several experts told Scientific American that there are high levels of biosecurity at the chicken facilities in order to avoid bird flu contamination.

    Alternatives to egg-based vaccines exist. Since the early 2010s, the U.S. Department of Health and Human Services has been partnering with CSL Seqirus, one of the largest influenza vaccine manufacturers, to develop vaccines grown in cells in a laboratory. The pandemic preparedness vaccine AUDENZ, which targets the H5N1 subtype specifically, is approved by the Food and Drug Administration. And although it’s impossible to determine which virus will cause the next pandemic, CSL Seqirus has a library of viruses that have the potential to infect humans. And the company is constantly looking for candidate vaccine viruses that it can tailor to a specific pathogen.

    “We use data [for] one of the avian strains to create a mock-up file,” says Marc Lacey, who runs CSL Seqirus’s pandemic preparedness and response team. The team members basically identify certain viruses, use them to create vaccines and conduct some of the early safety studies so that if an avian flu strain evolves into a true pandemic strain transmitting between humans, they will be ready to go with an adequate vaccine. Lacey says that his company would be able to supply the U.S. government with 150 million doses within the first six months of a pandemic being declared, but he thinks the scale-up potential could be higher, especially if multiple manufacturers could help produce it. Because there are eight billion people in the world, scale-up and widespread collaboration across countries would be necessary to make enough vaccine.

    There are also efforts to apply messenger RNA (mRNA) technology—such as that used for some of the COVID vaccines—to flu vaccines. According to University of Washington microbiologist Deborah Fuller, these efforts range from developing a universal flu vaccine to creating a “multivalent” vaccine that targets only a few subtypes—or versions of the virus (like a typical seasonal flu vaccine does). One advantage of mRNA technology is its speed of production. And because of the COVID pandemic, there is now more infrastructure to mass-produce doses. “RNA vaccines can be designed extremely quickly—you only need the genetic sequence of what the new variant is that’s emerging, and within weeks, [you] can have a vaccine already tested in animal models,” Fuller says.

    Scott Hensley, a professor of microbiology at the University of Pennsylvania, is also investigating mRNA flu vaccines. He’s part of a research team developing a 20-subtype mRNA flu vaccine that includes an H5N1 strain (although not the one currently circulating in birds). The team recently published its findings in Science. Hensley’s lab is now developing a single-strain vaccine tailored to the current bird flu strain—and is already testing it in laboratory animals. He emphasizes that, as with the COVID vaccines, his vaccines are meant to prevent serious illness and death, not infection.

    But even the 20-subtype vaccine is expected to provide some protection against the new strain. “When we developed [that] vaccine, the idea was to create one that could induce a certain level of immune memory against every subtype,” Hensley says. “Our goal wasn’t to predict which influenza subtype would cause the next pandemic or which strain would cause it. Rather the vaccine [would induce] some level of immune memory against every subtype so that it would limit disease and death caused by new pandemic strains.”

    A vaccine is only part of pandemic preparedness—you also need effective treatments. As Pavia says, researchers aren’t working from scratch trying to create something like the COVID antiviral Paxlovid, which took nearly two years to get to market. FDA-approved antivirals for influenza, such as Tamiflu, already exist and will be important for reducing deaths during a flu pandemic. Pavia is also hopeful that the U.S. could quickly adapt diagnostic tests to match an outbreak strain of pandemic flu.

    “We have better tools and better knowledge about influenza than we did about coronaviruses. In many ways, we would be a step ahead,” Pavia says. “But what I worry about is our political capacity to respond. We need to continue to [increase] awareness and continue preparation efforts. And if things start to accelerate, we need a concerted, nonpoliticized effort to move quickly and effectively.”

    Read The Full Article Here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Thimerosal carries no health risks and is almost never used anyway. So why are anti-vaxxers obsessed with it?

    June 30, 2025

    Altered gut microbiome linked to fertility issues in people with PCOS

    June 30, 2025

    Cold baths, climate shelters as Southern Europe heat wave intensifies

    June 29, 2025

    Roman army camp found in Netherlands, beyond the empire’s frontier

    June 29, 2025

    X-ray boosting fabric could make mammograms less painful

    June 28, 2025

    Why proposed changes to forestry rules won’t solve the ‘slash’ problem

    June 28, 2025
    popular posts

    Which Acts Most Often Help You ‘Max Out’ Your Workouts

    Google plans to expand its Google Lens multisearch tool, which

    Bestseller Sandra Brown Tackles One of Society’s Biggest Tragedies in

    Oceans Break Heat Record for Fourth Year in a Row

    Noah Cyrus Goes Braless in a Sheer Hooded Dress at

    Music-making and the flow of aerosols

    Pirates of Caribbean Producer Says Margot Robbie-Led Project is Still

    Categories
    • Books (3,258)
    • Cover Story (2)
    • Events (18)
    • Fashion (2,427)
    • Interviews (43)
    • Movies (2,558)
    • Music (2,836)
    • News (154)
    • Science (4,408)
    • Technology (2,551)
    • Television (3,280)
    • Uncategorized (932)
    Archives
    Facebook X (Twitter) Instagram Pinterest YouTube Reddit TikTok
    © 2025 Top Buzz Magazine. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT